Sutton Wealth Advisors’s Vanda Pharmaceuticals VNDA Stock Holding History

Sutton Wealth Advisors’s Portfolio VNDA Stock Details VNDA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,515	Closed	-$11.2K	–	1548
2022 Q4	$11.2K	Hold	1,515	–	–	﹤0.01%	905
2022 Q3	$15K	Buy	1,515 +726	+92%	+$7.67K	0.01%	757
2022 Q2	$8.6K	Buy	+789	New	+$8.18K	﹤0.01%	949
2022 Q1	–	Sell	-536	Closed	-$8.41K	–	1726
2021 Q4	$8.41K	Buy	536 +29	+6%	+$505	﹤0.01%	982
2021 Q3	$8.69K	Buy	507 +61	+14%	+$1.07K	﹤0.01%	958
2021 Q2	$9.59K	Buy	+446	New	+$7.98K	﹤0.01%	924
2020 Q3	–	Sell	-404	Closed	-$4.62K	–	1253
2020 Q2	$4.62K	Buy	+404	New	+$4.57K	﹤0.01%	924
2020 Q1	–	Sell	-667	Closed	-$10.9K	–	1260
2019 Q4	$10.9K	Buy	+667	New	+$10.1K	0.01%	797
2019 Q3	–	Sell	-896	Closed	-$12.6K	–	1221
2019 Q2	$12.6K	Sell	896 -70	-7%	-$1.11K	0.01%	721
2019 Q1	$17.8K	Hold	966	–	–	0.01%	620
2018 Q4	$25.2K	Buy	+966	New	+$22.7K	0.02%	446

Other funds holding VNDA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sutton Wealth Advisors's VNDA Position: Q1 2023 in Review

Sutton Wealth Advisors sold out of Vanda Pharmaceuticals (VNDA) in Q1 2023, closing a stake of 1,515 shares — an estimated $11.2K sold.

Sutton Wealth Advisors first reported a position in VNDA in Q4 2018 and held it in 11 quarters. The position peaked at $25.2K in Q4 2018. 177 funds tracked by Wall St. Rank hold VNDA as of Q1 2023.

Sutton Wealth Advisors reported no remaining Vanda Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Sutton Wealth Advisors sold 1,515 Vanda Pharmaceuticals shares in Q1 2023, an estimated $11.2K.
Sutton Wealth Advisors first reported a position in Vanda Pharmaceuticals in Q4 2018 and held it in 11 quarters.
Sutton Wealth Advisors's Vanda Pharmaceuticals position peaked at $25.2K in Q4 2018.
177 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2023.

Based on Sutton Wealth Advisors's 13F filing for Q1 2023, filed 7 Nov 2023.